RESUMEN
OBJECTIVES: The recurrence rate of benign endometrial polyps after a hysteroscopic polypectomy is low, between 0% and 15%. There are limited follow-up duration data on recurrence factors for benign polyps after hysteroscopic polypectomy, including recurrences with Versapoint® versus resectoscope. This study aims to estimate the rate of symptomatic recurrence following hysteroscopic polypectomy and to analyze the possible risk factors involved with Versapoint® versus resectoscope. MATERIALS AND METHODS: We designed a retrospective cohort study in a tertiary university hospital in Seville (Spain) which looked at the results of polypectomy with a 9-mm resectoscope on 42 women between 2008 and 2015 compared to 151 women using Versapoint® during 2014. RESULTS: The rate of first recurrence was 24.35%. There was a strong positive correlation between the recurrence and the follow-up duration (odds ratio [OR] = 2.58; 95% confidence interval [CI] = 1.68-5.04; P = 0.000), the polyps causing abnormal uterine bleeding (OR = 2.5; 95% CI: 1.1-3; P = 0.04), and a polyp size >15 mm (OR = 1.63; 95% CI = 1.3-3.1; P = 0.02). There were no statistical differences in polyps' recurrence among the types of hysteroscopic polypectomy (P > 0.05). CONCLUSION: The main risk factors for recurrence were polyps causing abnormal uterine bleeding, size, and follow-up duration.
RESUMEN
Objective: To describe the 3-dimensional hysterosalpingo-contrast sonography (3D-HyCoSy) technique and analyze our results with 2 contrast agents: SonoVue® and ExEm Foam®. Material and methods: Cross-sectional study of 160 infertility patients with unknown tubal patency. Results: Bilateral tubal patency was diagnosed in 102/153 (66.7%) patients. A similar proportion of bilateral occlusion was observed with both SonoVue® 5/87 (5.7%) and ExEm foam® 4/66 (6.1%) (p = 0.52). Intrauterine disease was suspected in 33/155 (21.3%) patients: 20% (18/90) with SonoVue® and 23.1% (15/65) with ExEm Foam® (p = 0.644). The visual analog scale (VAS) revealed mild pain (VAS ≤ 4: 86.4% [70/81] with SonoVue® vs. 86.8% [59/68]) with ExEm Foam® (p = 0.951). A pediatric nasogastric probe was easily used to cannulate the cervical os in 128/159 (80.5%) cases. The volume of ExEm foam® used was lower than that of SonoVue® (median: 3 cc vs.20 cc, p < 0.001). Conclusion: 3D-HyCoSy is a reliable, well-tolerated, and effortless tool for the sonographic assessment of sterility. The results were similar with both contrast agents (AU)
Objetivo: describir la técnica y analizar nuestros resultados con histerosonosalpingografía con contraste 3D (HyCoSy-3D) utilizando SonoVue® y Exem Foam®. Material y métodos: estudio retrospectivo de corte transversal en 160 pacientes estériles con permeabilidad tubárica desconocida. Resultados: l 66,7% (102/153) de las pacientes tuvo permeabilidad tubárica bilateral. El diagnóstico de obstrucción tubárica bilateral fue similar utilizando SonoVue® 5/87 (5,7%) y Exem Foam® 4/66 (6,1%), p = 0,52. Diagnosticamos patología intrauterina en 33/155 (21,3%) de las pacientes, 20% (18/90) con SonoVue® vs. 23,1% (15/65) p = 0,644. El dolor percibido resultó leve en la mayoría de los casos (escala visual analógica ≤ 4; 86,4% (70/81) SonoVue® vs. 86,8% (59/68), p = 0,951). La canalización cervical fue sencilla con sonda nasogástrica pediátrica en 128/159 (80,5%). Exem Foam® precisó un menor volumen instilado (mediana: 3 cc vs. 20 cc, p < 0,001). Conclusiones: la HyCoSy-3D es una prueba tolerable, sencilla y rentable para el estudio ecográfico en esterilidad. Ambos contrastes mostraron similares resultados (AU)